Daan van den Broek
Overview
Explore the profile of Daan van den Broek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kramer A, van Schaik L, van den Broek D, Meijer G, Gutierrez Ibarluzea I, Galnares Cordero L, et al.
Pharmacoeconomics
. 2025 Feb;
PMID: 39920559
Background: Cost-effectiveness analysis (CEA) of biomarkers is challenging due to the indirect impact on health outcomes and the lack of sufficient fit-for-purpose data. Hands-on guidance is lacking. Objective: We aimed...
2.
Medina J, Annapragada A, Lof P, Short S, Bartolomucci A, Mathios D, et al.
Cancer Discov
. 2024 Sep;
15(1):105-118.
PMID: 39345137
There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that...
3.
Rubio-Alarcon C, Stelloo E, Vessies D, van t Erve I, Mekkes N, Swennenhuis J, et al.
J Mol Diagn
. 2024 Sep;
26(12):1065-1080.
PMID: 39332629
Structural variants (SVs) caused by chromosomal rearrangements in common fragile sites or long interspersed nuclear element (LINE) retrotranspositions are highly prevalent in colorectal cancer. However, methodology for the targeted detection...
4.
Kramer A, Greuter M, Schraa S, Vink G, Phallen J, Velculescu V, et al.
Ther Adv Med Oncol
. 2024 Aug;
16:17588359241266164.
PMID: 39175989
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative...
5.
van der Wel J, Boelens M, Jebbink M, Smulders S, Maas K, Luitse M, et al.
Neuro Oncol
. 2024 Aug;
26(12):2316-2327.
PMID: 39110039
Background: Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC) is challenging. We aimed to identify resistance mechanisms (RM) to...
6.
Yeghaian M, Bucho T, de Bruin M, Schmitz A, Bodalal Z, Smit E, et al.
J Cancer Res Clin Oncol
. 2024 Jun;
150(6):329.
PMID: 38922374
Purpose: In this study, we aimed to evaluate the potential of routine blood markers, serum tumour markers and their combination in predicting RECIST-defined progression in patients with stage IV non-small...
7.
van der Leest P, Rozendal P, Hinrichs J, van Noesel C, Zwaenepoel K, Deiman B, et al.
Clin Chem
. 2024 Mar;
70(5):759-767.
PMID: 38484302
Background: Identification of tumor-derived variants in circulating tumor DNA (ctDNA) has potential as a sensitive and reliable surrogate for tumor tissue-based routine diagnostic testing. However, variations in pre(analytical) procedures affect...
8.
Gaillard D, Lof P, Sistermans E, Mokveld T, Horlings H, Mom C, et al.
Int J Gynecol Cancer
. 2024 Feb;
34(5):713-721.
PMID: 38388177
Objective: To assess the feasibility of scalable, objective, and minimally invasive liquid biopsy-derived biomarkers such as cell-free DNA copy number profiles, human epididymis protein 4 (HE4), and cancer antigen 125...
9.
Kramer A, Rubio-Alarcon C, van den Broek D, Vessies D, Vant Erve I, Meijer G, et al.
Mol Oncol
. 2023 Dec;
18(11):2730-2742.
PMID: 38060377
Circulating tumor DNA (ctDNA) detection has multiple promising applications in oncology, but the road toward implementation in clinical practice is unclear. We aimed to support the implementation process by exploring...
10.
van Veggel B, van der Wekken A, Paats M, Hendriks L, Hashemi S, Daletzakis A, et al.
Cancer
. 2023 Oct;
130(5):683-691.
PMID: 37905752
Background: Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are the third most common EGFR mutations in patients with non-small cell lung cancer (NSCLC) and are associated with...